Published in:
Open Access
01-12-2011 | Erratum
Erratum to:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
Authors:
Samuel Frank, Huntington Study Group/TETRA-HD Investigators
Published in:
BMC Neurology
|
Issue 1/2011
Login to get access
Excerpt
After publication of this work [
1], we became aware of a typographical error. The term dysphagia inadvertently replaced the term dysarthria in two instances. Dysarthria was statistically significantly worsened at week 80 compared to baseline, whereas there was only a statistical trend (p = 0.10) for dysphagia at week 80 compared to baseline. Dysphagia continues to be an issue in patients with Huntington Disease and was reported as an adverse event in this study. Therefore, clinicians who prescribe tetrabenazine should still monitor their patients for worsening swallowing, but the worsening was not statistically different in those who completed this trial. No further studies of tetrabenazine in Huntington Disease have been completed since the publication of this study. …